Severe pediatric asthma therapy: Omalizumab-A systematic review and meta-analysis of efficacy and safety profile.

ABSTRACT:

Background

Omalizumab is the first biological therapy used to treat moderate-to-severe asthma and certainly the one with the highest number of publications.

Methods

A systematic review and meta-analysis were performed to examine two critical outcomes of omalizumab therapy, asthma exacerbation rate, the reduction of the use of inhaled corticosteroids (ICS), and the improvement of the lung function as a secondary outcome using the following keywords in the MEDLINE database: "anti-IgE, severe asthma, children, and randomized controlled trial." We specifically selected papers that included moderate-to-severe asthma patients and collected data on children and adolescents.

Results

Four RCT studies (total number of patients = 1,239) were included in the analysis. The reporte

SUBMITTER: Fenu G 

PROVIDER: S-EPMC10020639 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature